Merck's Oral PCSK9 Inhibitor Shows Significant LDL-C Reductions

Enlicitide Decanoate demonstrated greater efficacy in lowering LDL cholesterol compared to placebo in clinical trials.

Mar. 30, 2026 at 5:11pm

Got story updates? Submit your updates here. ›

Merck has announced positive results from a clinical trial of its investigational oral PCSK9 inhibitor, Enlicitide Decanoate. The drug demonstrated significantly greater reductions in low-density lipoprotein cholesterol (LDL-C) levels compared to placebo after eight weeks of treatment.

Why it matters

PCSK9 inhibitors are an important class of cholesterol-lowering medications that work by reducing the amount of LDL cholesterol in the blood. An oral formulation could improve patient convenience and adherence compared to injectable PCSK9 inhibitors currently on the market.

The details

In the Phase 2 clinical trial, Enlicitide Decanoate was evaluated in patients with elevated LDL-C levels. The drug showed a statistically significant reduction in LDL-C levels compared to placebo at the eight-week timepoint. The trial also assessed the safety and tolerability of the investigational oral PCSK9 inhibitor.

  • The clinical trial results were announced on March 30, 2026.

The players

Merck

A major American pharmaceutical company that develops and markets a wide range of medications, vaccines, and other healthcare products.

Enlicitide Decanoate

Merck's investigational oral PCSK9 inhibitor medication that is being evaluated for its ability to lower LDL cholesterol levels.

Got photos? Submit your photos here. ›

What’s next

Merck plans to advance Enlicitide Decanoate into late-stage clinical trials to further evaluate its efficacy and safety for potential regulatory approval.

The takeaway

The positive results for Merck's oral PCSK9 inhibitor represent an important step forward in the development of more convenient cholesterol-lowering treatments that could improve patient adherence and access to this class of medications.